Jazz Pharmaceuticals to Acquire Actio Biosciences for $820 Million, Securing First-in-Class KCNT1 Epilepsy Therapy ABS-1230
核心洞察
Jazz Pharmaceuticals announced a definitive agreement to acquire Actio Biosciences (搜索) for $820 million upfront, with up to $500 million in contingent milestones.
The acquisition centers on ABS-1230, a first-in-class oral small molecule KCNT1 (搜索) ion channel inhibitor for KCNT1+ epilepsy (搜索), a rare genetic disorder with no FDA-approved therapies.
ABS-1230 has demonstrated meaningful seizure reductions in an early proof-of-concept trial and holds FDA Fast Track, Rare Pediatric Disease, Orphan Drug, and RDEP designations.
Jazz Pharmaceuticals and Actio Biosciences (搜索) announced on August 10, 2026 that they have entered into a definitive agreement under which Jazz will acquire the privately-held biotechnology company for $820 million upfront, with up to $500 million in additional contingent consideration tied to approval and sales milestones. The transaction, unanimously approved by both companies' boards, is expected to close by the fourth quarter of 2026.
The acquisition is anchored by ABS-1230, Actio's lead clinical asset and a potential first-in-class precision therapy for KCNT1 (搜索)-related epilepsy — a rare genetic developmental and epileptic encephalopathy (DEE) for which no FDA-approved therapies currently exist.
A Precision Approach to a Devastating Pediatric Epilepsy
KCNT1+ epilepsy (搜索) affects approximately 2,500 patients in the United States. The disease imposes a profound seizure burden, with most patients experiencing dozens to hundreds of episodes daily that remain highly resistant to standard antiseizure medications. Approximately 80% of affected individuals experience disease onset during infancy, and many of these children never achieve fundamental developmental milestones such as walking or speaking. Some do not survive into adulthood. For those with later-onset disease, the condition typically manifests as disruptive nocturnal seizures accompanied by significant cognitive and psychiatric comorbidities.
ABS-1230 is designed as a potent and selective orally available small molecule KCNT1 (搜索) ion channel inhibitor. In preclinical studies, the compound inhibited KCNT1 across all evaluable pathogenic mutations, suggesting potential to treat all patients with KCNT1-related epilepsy. In an early clinical proof-of-concept trial, children with KCNT1-related epilepsy who received ABS-1230 experienced meaningful seizure reductions.
Regulatory Momentum and the KYRON Trial
ABS-1230 has secured multiple FDA designations that underscore both the severity of the unmet need and the agency's interest in facilitating rapid development: Fast Track, Rare Pediatric Disease, and Orphan Drug Product designations. Notably, the therapy has also been accepted into the FDA's new Rare Disease Evidence Principles (RDEP) program, which aims to accelerate the development of ultra-rare disease therapies.
The ongoing Phase 1b/2a KYRON trial is designed to serve as the registrational study to support a new drug application submission in the United States.
Strategic Rationale and Leadership Commentary
"The acquisition of ABS-1230 represents a highly strategic expansion of our rare epilepsy portfolio, building upon the global success of Epidiolex and deepening our leadership in rare and severe epilepsies," said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals. "The emerging clinical profile of ABS-1230 is highly encouraging, and we look forward to closing the proposed transaction and collaborating with our new Actio Biosciences (搜索) colleagues to address an urgent patient need."
David Goldstein, Ph.D., chief executive officer of Actio Biosciences (搜索), emphasized the fit between the two organizations: "We chose to partner with Jazz because they combine a purpose-led culture with a world-class development engine and the commercial scale to ensure ABS-1230 is brought to patients as quickly and efficiently as possible."
Transaction Structure and Spin-Out
Jazz will fund the transaction through a combination of cash on hand and drawing on existing financing facilities. Concurrently with closing, Actio Biosciences (搜索) will spin out a new privately-held entity housing certain management, employees, and assets not including ABS-1230. The new company, funded by existing investors, will focus on genetic rare neurological diseases, including a clinical-stage small molecule TRPV4 (搜索) inhibitor, ABS-0871, for Charcot-Marie-Tooth type 2C (搜索) and other early-stage programs. Jazz will receive a minority stake and certain related rights in the new entity.
Moelis & Company LLC is serving as financial advisor to Jazz Pharmaceuticals, with Hogan Lovells Cadwalader US LLP as legal advisor. J.P. Morgan Securities LLC and Centerview Partners LLC are serving as financial advisors to Actio Biosciences (搜索), with Cooley LLP as legal advisor.